Norvasc®, a calcium channel blocker, with an established record of efficacy and safety in the treatment of hypertension was being challenged by agents in a new class of drugs called ARBs. These newer agents were gaining in popularity and, in fact, went on to do very well. But at the time their supporting data were limited and we tried to communicate that in a compelling way. In the end, the client did not produce it, but it remains one of our favorites.